Results 251 to 260 of about 103,961 (275)

Ipilimumab/nivolumab/nivolumab/pembrolizumab

Reactions Weekly, 2023
openaire   +1 more source

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Lancet, The, 2021
Kohei Shitara, Markus Moehler, Marcelo Garrido   +2 more
exaly  

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Lancet, The, 2021
Paul Baas, Arnaud Scherpereel, Anna K Nowak   +2 more
exaly  

Ipilimumab/nivolumab/nivolumab

Reactions Weekly
  +4 more sources

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Lancet, The, 2022
Bastian Schilling, Christian Menzer, Friedegund Meier   +2 more
exaly  

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

Lancet, The, 2022
Dukagjin Blakaj, Kenneth Y Tsai, Zeynep EroĞlu   +2 more
exaly  

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet, The, 2020
Lisa Zimmer, Elisabeth Livingstone, Jessica C Hassel   +2 more
exaly  

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Lancet, The, 2023
Laurence Albiges, Yoshihiko Tomita, Burcin Simsek   +2 more
exaly  

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

New England Journal of Medicine, 2022
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson   +2 more
exaly  

Nivolumab

Reactions Weekly
  +4 more sources